TURINABOL

Turinabol (dehydrochloromethyltestosterone, DHCMT) was developed by Jenapharm in East Germany and was notoriously used in state-sponsored doping programs. Pharmacokinetic studies in humans show near-complete oral absorption with peak plasma concentrations at approximately 3 hours, though a significant first-pass effect reduces systemic availability of the parent drug. The terminal half-life is approximately 16 hours with evidence of enterohepatic circulation. Metabolism is extensive, involving multiple cytochrome P450 enzymes including CYP11B1, CYP11B2, CYP46A1, and CYP21A2, producing numerous hydroxylated metabolites. Long-term metabolites such as 20βOH-NorDHCMT can be detected in urine for over 22 days post-administration, making doping detection highly effective. Clinical evidence for efficacy and safety is limited, as the compound was never formally approved for widespread medical use and most data comes from doping control and metabolism studies rather than controlled clinical trials.